SUPPLEMENTAL MATERIALS

The Effectiveness of Ixekizumab and Other b/tsDMARDs at 12 Weeks for Patients With PsA in Real-World Settings: Results From the PRO-SPIRIT Study

Hasan Tahir,[1] William Tillett,[2] Vinod Chandran,[3] Khai Jing Ng,[4] Marcus Ngantcha,[4] Cedric Laedermann,[4] Hagen Russ,[4] Rieke Alten,[5] Lars Erik Kristensen,[6] Dennis McGonagle[7]

[1]Royal Free NHS Trust, London, United Kingdom; [2]University of Bath, Bath, United Kingdom; [3]University of Toronto, Toronto, Canada; [4]Eli Lilly and Company, Indianapolis, USA; [5]Schlosspark-Klinik, Berlin, Germany; [6]The Parker Institute, University of Copenhagen, Copenhagen, Denmark; [7]Leeds University, Leeds, United Kingdom

On-Label Population (N=996) Baseline Demographics and Clinical Characteristics

Baseline	IXE (N=321)	Other b/tsDMARDs				
		TNFi (N=432)	IL-12/23i (N=33)	IL-23i (N=56)	JAKi (N=122)	PDE4i (N=32)
Age, years	53.9 (12.1)	51.0 (12.2)	50.3 (11.8)	52.7 (11.7)	52.9 (12.4)	54.8 (9.2)
Female, n (%)	211 (65.7)	260 (60.2)	17 (51.5)	33 (58.9)	79 (64.8)	20 (62.5)
Time since PsA diagnosis, years	9.3 (8.6)	6.6 (7.3)	7.8 (8.9)	8.9 (8.1)	9.0 (7.6)	8.8 (7.7)
Monotherapy at BL, n (%)	207 (64.5)	198 (45.8)	26 (78.8)	39 (69.6)	64 (52.5)	24 (75.0)
Prior b/tsDMARD, n (%)	223 (69.5)	134 (31.0)	24 (72.7)	43 (76.8)	89 (73.0)	7 (21.9)
SJC (0-66)	4.9 (6.0)	4.7 (5.4)	4.3 (5.8)	3.6 (4.4)	5.6 (7.2)	3.0 (4.1)
TJC (0-68)	10.4 (10.4)	10.3 (10.7)	9.1 (9.5)	10.6 (11.5)	11.8 (11.2)	7.9 (9.5)
BSA ≥3% involvement, n (%)	136 (42.4)	148 (34.3)	17 (51.5)	31 (55.4)	32 (26.2)	16 (50.0)

Note: Data are mean (SD) unless stated otherwise
b/tsDMARD=biologic/targeted synthetic disease-modifying anti-rheumatic drug; BL=baseline; BSA=body surface area; IL=interleukin; IL-12/23i=IL-12/23 inhibitor; IL-23i=IL-23 inhibitor; IXE=ixekizumab; JAKi=janus kinase inhibitor; PDE4i=phosphodiesterase-4 inhibitor; PsA=psoriatic arthritis; SJC=swollen joint count; TJC=tender joint count; TNFi=tumor necrosis factor inhibitor

On-Label Population (N=996) Outcomes at Baseline and Week 12

Baseline	IXE (N=321)	Other b/tsDMARDs				
		TNFi (N=432)	IL-12/23i (N=33)	IL-23i (N=56)	JAKi (N=122)	PDE4i (N=32)
CFB in SJC (0-66), mean (SE)	-2.7 (0.3)	-2.7 (0.3)	-1.0 (1.0)	-1.1 (0.5)	-3.1 (0.6)	-1.7 (0.9)
Baseline, mean (95% CI)	4.9 (4.2-5.6)	4.7 (4.2-5.2)	4.3 (2.2-6.3)	3.6 (2.4-4.8)	5.6 (4.3-6.9)	3.0 (1.6-4.5)
Week 12, mean (95% CI)	2.2 (1.7-2.6)	2.0 (1.7-2.3)	3.4 (1.6-5.3)	2.3 (1.3-3.4)	2.5 (1.7-3.3)	1.2 (0.4-2.0)
CFB in TJC (0-68), mean (SE)	-4.3 (0.6)	-4.3 (0.4)	-1.0 (1.6)	-3.9 (1.3)	-5.1 (1.1)	-2.5 (1.8)
Baseline, mean (95% CI)	10.4 (9.3-11.6)	10.3 (9.3-11.4)	9.1 (5.7-12.5)	10.6 (7.6-13.7)	11.8 (9.8-13.8)	7.9 (4.5-11.3)
Week 12, mean (95% CI)	6.1 (7.1-5.0)	6.2 (5.4-7.1)	8.0 (4.3-11.8)	6.7 (4.7-8.8)	6.8 (4.8-8.9)	5.6 (2.9-8.3)
Week 12 cDAPSA						
REM (0 to ≤4), n (%)	38 (12.5)	56 (13.6)	5 (16.1)	4 (7.4)	16 (13.7)	5 (17.2)
LDA (>4 to ≤13), n (%)	96 (31.5)	119 (29.0)	6 (19.4)	13 (24.1)	37 (31.6)	7 (24.1)
Moderate DA (>13 to ≤ 27), n (%)	133 (43.6)	184 (44.8)	27 (50.0)	27 (50.0)	42 (35.9)	14 (48.3)
High DA (>27), n (%)	38 (12.5)	52 (12.7)	10 (18.5)	10 (18.5)	22 (18.8)	3 (10.3)
CFB in % BSA, mean (SE)	-3.2 (0.6)	-1.5 (0.5)	-2.1 (1.5)	-4.1 (1.6)	-1.4 (0.6)	-1.7 (1.2)
Baseline, mean (95% CI)	5.5 (4.3-6.6)	4.4 (3.5-5.3)	6.2 (3.0-9.3)	7.9 (4.5-11.3)	3.1 (1.6-4.6)	4.4 (2.5-6.4)
Week 12, mean (95% CI)	2.4 (1.8-2.9)	2.8 (2.2-3.5)	4.4 (6.9-2.0)	3.9 (2.0-5.8)	1.7 (0.9-2.5)	2.8 (1.3-4.2)
BSA shift ≥3% to <3%, n (%)[a]	79 (58.1)	62 (41.9)	4 (23.5)	14 (45.2)	17 (53.1)	5 (31.3)
MDA						
Baseline, % response (95% CI)	4.4 (2.1-6.6)	6.9 (4.6-9.3)	18.2 (5.0-31.3)	3.6 (0.0-8.4)	6.6 (2.2-11.0)	6.3 (0.0-14.6)
Week 12, **%** response (95% CI)	25.8 (20.7-31.0)	25.9 (21.5-30.3)	23.8 (8.4-39.2)	17.7 (7.1-28.4)	24.6 (16.4-32.8)	35.4 (16.8-54.0)
MDA in patients with BL BSA ≥3%						
Baseline, % response (95% CI)	5.1 (1.4-8.9)[b]	3.4 (0.5-6.3)[c]	29.4 (7.8-51.1)[d]	0.0 (0.0)[e]	0.0 (0.0)[f]	6.3 (0.0-18.1)[g]
Week 12, % response (95% CI)	27.8 (19.7-35.9)[b]	25.8 (18.3-33.2)[c]	37.2 (13.4-60.9)[d]	19.4 (4.6-34.2)[e]	10.9 (0.0-22.6)[f]	41.1 (14.5-67.7)[g]

[a] Denominator is number of patients with BSA ≥3% at BL; [b] n=136; [c] n=148; [d] n=17; [e] n=31; [f] n=32; [g] n=16

b/tsDMARD=biologic/targeted synthetic disease-modifying anti-rheumatic drug; BL=baseline; BSA=body surface area; cDAPSA=Clinical DAPSA; CFB=change from baseline; CI=confidence interval; DA=disease activity DAPSA=Disease Activity Index for PSoriatic Arthritis; IL=interleukin; IL-12/23i=IL-12/23 inhibitor; IL-23i=IL-23 inhibitor; IXE=ixekizumab; JAKi=janus kinase inhibitor; LDA=low disease activity; MDA=Minimal Disease Activity; PDE4i=phosphodiesterase-4 Inhibitor; REM=remission; SJC=swollen joint count; TJC=tender joint count; TNFi=tumor necrosis factor inhibitor

Abbreviations

b/tsDMARD=biologic/targeted synthetic DMARD; BL=baseline; BSA=body surface area; cDAPSA=clinical DAPSA; CFB=change from baseline; CI=confidence interval; DA=disease activity; DAPSA=Disease Activity Index for PSoriatic Arthritis; DMARD=disease-modifying anti-rheumatic drug; IL=interleukin; IL-12/23i=IL-12/23 inhibitor; IL-23i=IL-23 inhibitor; IL-17Ai=IL-17A inhibitor; IXE=ixekizumab; JAKi=janus kinase inhibitor; LDA=low disease activity; M=month; MDA=Minimal Disease Activity; N=number of patients in the specified treatment group; n=number of patients with an observation; PDE4i=phosphodiesterase-4 inhibitor; PRO-SPIRIT=PsA Observational Study of Persistence of Treatment; PsA=psoriatic arthritis; REM=remission; SD=standard deviation; SE=standard error; SJC=swollen joint count; TJC=tender joint count; TNFi=tumor necrosis factor inhibitor